Jun Qi, PhD
Dana-Farber Cancer Institute
Dr. Qi is a well-trained synthetic chemist, chemical biologist, and biologist with an interdisciplinary background in drug development. His research is focused on designing and developing biologically relevant small molecule inhibitors and degraders of epigenetic protein targets and utilizing these chemical tools to study the translational potential of these targets in cancers, including blood cancer.
Dr. Ken Anderson is well-known physician scientist who studies and treats MM. His research has led to a variety of novel therapies for clinical MM treatment.
Together, this team has brought multiple targets into potential treatment development for MM, including HDACs, KDMs, and RPN13. The complementary expertise between these two PIs will uncover novel biological insights into MM that can bring novel therapies into other hematological malignancies.